Navigation Links
Diabetes Drug Byetta Caused Arkansas Man’s Pancreatic Cancer and Resulting Injuries, Alleges Lawsuit Filed by Parker Waichman LLP and Co-Counsel
Date:5/30/2013

New York, New York (PRWEB) May 30, 2013

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, and The Drakulich Firm, based in San Diego, have filed a lawsuit on behalf of an Arkansas man who developed pancreatic cancer and resulting injuries allegedly from using the diabetes drug Byetta. The suit was filed on May 28, 2013, in the U.S. District Court for the Southern District of California (Case No. 13-cv-99999). Amylin Pharmaceuticals LLC, Amylin Pharmaceuticals Inc. and Eli Lilly and Co. have so far been named as Defendants.

According to the Complaint, the Plaintiff was prescribed and injected Byetta to treat his diabetes beginning around 2007 and continued using it at least until June 2012. On or about Feb. 25, 2013, a CT scan determined that the Plaintiff had pancreatic adenocarcinoma, the most common form of pancreatic cancer. Once diagnosed, the Plaintiff began treatment, which included chemotherapy and radiation therapy. He went on to develop jaundice.

The Complaint alleges that the Defendants knew or should have known that Byetta caused serious side effects, yet they continued to market and sell the drug by providing false and misleading information. The suit seeks damages for extensive pain and suffering, and severe emotional distress, among other things.

Byetta was approved by the U.S. Food Drug Administration (FDA) in 2005. It falls into a class of drugs called incretin mimetics, which work by mimicking the incretin hormones that the body usually naturally produces to stimulate the release of insulin after a meal. The drugs are used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.

The Institute for Safe Medication Practices (ISMP) revealed in its most recent QuarterWatch report that glucagon-like peptide-1 (GLP-1) agents – such as Byetta, Victoza, Januvia, Onglyza (saxagliptin) and Tradjenta (linagliptin) – are 25 times more likely to be linked to pancreatic cancer. The report, issued on April 18th, used information from the FDA’s adverse event report database to analyze a year’s worth of reports related to the type 2 diabetes drugs. ISMP found that there were 105 cases of pancreatic cancer linked to these medications, compared to a different class of diabetes drugs; 71 of those cases were associated with Byetta. The watchdog group also found that injectable incretin mimetics were 28 times more likely to be associated with pancreatitis, or inflammation of the pancreas, while oral agents were 20 times more likely to lead to the condition.

On March 14, 2013, the FDA announced that it was investigating incretin mimetic drugs after researchers found evidence of pancreatitis and pre-cancerous cell changes known as pancreatic duct metaplasia. According to the FDA, incretin mimetic drugs include: exenatide (Byetta, Bydureon), liraglutide (Victoza), sitagliptin (Januvia, Janumet, Janumet XR, Juvisync), saxagliptin (Onglyza, Kombiglyze XR), alogliptin (Nesina, Kazano, Oseni), and linagliptin (Tradjenta, Jentadueto).

Parker Waichman LLP continues to offer free legal consultations to victims of alleged Byetta injuries, including bladder cancer, heart problems, and eye injuries. If you or a loved one were diagnosed with bladder cancer after taking Byetta, please contact their office by visiting yourlawyer.com. Free case evaluations are also available by calling 1-800-LAW-INFO (1-800-529-4636).

Contact:
Parker Waichman LLP
Gary Falkowitz, Managing Attorney
(800) LAW-INFO
(800) 529-4636
http://www.yourlawyer.com

Read the full story at http://www.prweb.com/releases/byetta_lawsuit/05/prweb10784988.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. How a cancer drug leads to diabetes
2. Heart failure patients with diabetes may benefit from higher glucose levels
3. Disrupted Sleep May Raise Risk for Obesity, Diabetes: Study
4. Mouse Study Hints at New Path for Diabetes Treatment
5. Common Plastics Chemical Might Boost Diabetes Risk
6. Weight-Loss Surgery Beat Drugs for Cutting Diabetes in Very Obese
7. Naturopathic care can improve blood sugar, mood in diabetes
8. Cellular pathway linked to diabetes, heart disease
9. Diabetes Groups Issue New Guidelines on Blood Sugar
10. Value of Metformin, Insulin Combo for Type 2 Diabetes Questioned
11. Xenotransplantation as a therapy for type 1 diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh ... the Peace Agreements being discussed by President Donald Trump and the rest of the ... to speed up peace talks in the continuous battle between Israel and Palestine. The ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... “When the ... Lead Home” is the creation of published author Laura Weigel Douglas, an avid reader ... cat in a house that sometimes feels like Green Hills Adventure Camp. She couldn’t ...
(Date:5/26/2017)... ... May 26, 2017 , ... “Cactus Jack: Against All Odds”: ... many others. “Cactus Jack: Against All Odds” is the creation of published author, ... Hubbard is married to Jack Carlisle’s third child Jane. Walter. Walter and Jane ...
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... Dr. Alan ... surgery in New York City. He is known for his distinguished expertise and ... vascular surgery, Dr. Benvenisty holds sub-specialty training in treating renovascular disease and aortic ...
(Date:5/24/2017)... ... ... Dr. Manju R. Kejriwal, a leading Ohio dentist, is now welcoming new ... Dr. Kejriwal understands the emotional and financial toll traditional orthodontics can take on patients’ ... longer need to feel the esthetic effects of wires and brackets when they can ...
Breaking Medicine News(10 mins):
(Date:5/18/2017)... May 17, 2017  Bayer announced today that the ... be presented at the 53 rd Annual Meeting ... place June 2-6 in Chicago . ... span prostate, colorectal, liver and thyroid cancers, as well ... Phase II CHRONOS-1 trial of copanlisib in patients with ...
(Date:5/15/2017)... 2017 Enterin Inc., a privately-held CNS pharmaceutical company ... compounds to treat Parkinson,s disease (PD), has enrolled the first ... 1/2a randomized, controlled, multicenter study involving patients with PD and ... patients over a 9-to-12-month period. The first stage is open ... PD. Participating sites include Denver , ...
(Date:5/11/2017)...  Thornhill Research Inc. ( Toronto, Ontario, ... USD five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery contract by the U.S. ... (CCC) ( Ottawa, Ontario, Canada ) ... anesthesia to patients requiring emergency medical procedures in ... Corps have been a longtime partner with Thornhill ...
Breaking Medicine Technology: